TIANCHAO INSIGHTS

Tianchao Insights

From the intersection of the healthcare industry and capital markets, we share professional insights that influence corporate strategy and transaction decisions.

September 23, 2026

Industry Trends

2026 Healthcare Investment Trends: Which Segments Still Attract Capital?

In 2026, healthcare investment is shifting from broad bets to a focus on technology barriers, clinical value, commercialization capabilities, and asset quality. This article analyzes capital trends in innovative drugs, biotech, medical devices, AI in healthcare, diagnostics, healthcare services, and cross-border innovation, and summarizes how healthcare companies can enhance their financing and strategic transaction capabilities.

September 23, 2026

Capital Strategy

Healthcare Company Financing Enters a New Phase: Shifting from 'Financing Amount' to 'Capital Efficiency'

The logic of healthcare company financing is changing. Instead of solely pursuing large financing amounts, companies need to focus more on capital efficiency, use of funds, R&D and commercialization milestones, valuation management, industrial synergy, and the ability to secure the next round of funding.

September 23, 2026

Capital Strategy

The Underlying Logic of M&A in the Healthcare Industry: From Financial Investment to Industrial Synergy

M&A in the healthcare industry is gradually shifting from a pure pursuit of financial returns to strategic synergy centered around products, technology, channels, R&D, commercialization, and industrial chain resources. This article analyzes how healthcare companies can assess the true value of an M&A transaction from the perspectives of M&A motives, synergy value, transaction types, due diligence, and integration execution.

September 23, 2026

Strategic Viewpoints

License-out vs. License-in: How to Design International BD Strategies for Healthcare Companies?

License-out and License-in are important transaction models for healthcare companies to achieve internationalization and commercial value of innovative assets. This article analyzes how healthcare companies can design international BD strategies from the perspectives of asset positioning, regional rights, partner selection, transaction structure, due diligence, commercialization capabilities, and cross-border BD strategies.

September 23, 2026

industry

Innovative Drug Companies: Licensing vs. M&A - How to Choose?

How should innovative drug companies choose between licensing and M&A? This article analyzes the two value realization paths of licensing and M&A from the perspectives of asset maturity, capital needs, commercialization capabilities, strategic control, transaction structure, risk allocation, and exit paths, and provides a transaction decision-making framework applicable to innovative drug companies.

September 23, 2026

Medical Devices

Why Do Medical Device Companies Increasingly Need to Rely on M&A for Growth?

The medical device industry has entered a new stage where inventory competition and rapid technological iteration coexist. This article analyzes why medical device companies are paying more and more attention to M&A, the role of M&A in product line expansion, technology acquisition, market entry, scale effects, and strategic transformation, and discusses how companies can determine whether M&A is a suitable path for growth.

September 22, 2026

Capital Strategy

Healthcare Company Financing Valuation: What Key Metrics Do Investors Typically Focus On?

When a healthcare company seeks financing, how do investors determine its valuation? This article analyzes the valuation logic for healthcare companies at different stages of development, based on key metrics such as revenue growth, gross margin, cash flow, market size, product pipeline, clinical and regulatory progress, commercialization capabilities, competitive barriers, and capital efficiency.

September 21, 2026

Capital Strategy

How Do Healthcare Companies Determine Whether the Current Stage is Suitable for Financing?

For healthcare companies, it's not always better to raise capital earlier, nor is it wise to wait until cash is low. This article analyzes how healthcare companies can determine whether the current stage is suitable for initiating financing from the dimensions of corporate development stage, core value milestones, funding needs, financing window, valuation, and capital structure.

April 22, 2026

M&A and Transactions

Key Challenges in Cross-Border Healthcare M&A: Strategy, Integration, and Regulation

As Chinese healthcare companies go global, cross-border M&A faces multiple challenges in strategic fit, regulation, integration, and commercialization.

April 15, 2026

M&A and Transactions

Healthcare Company Valuation Methods: From Comparable Company Analysis to rNPV

Healthcare company valuation has distinct industry characteristics. This article introduces common valuation logics for innovative drugs, medical devices, and companies at different stages of development.

April 15, 2026

Valuation

Analysis of Medical Company Valuation Methods: From rNPV to Comparable Company Analysis

The valuation of a medical company requires a comprehensive judgment based on factors such as the R&D stage, clinical data, commercialization capabilities, cash flow, and comparable companies.

April 10, 2026

M&A and Transactions

What Does Biotech License-out Mean? Understanding Innovative Drug Licensing Transactions

Understanding international licensing transactions for innovative drugs from the perspectives of license-out deal structure, transaction value, payment arrangements, and corporate strategy.

LET'S TALK

Stay Ahead of the Next Wave in Healthcare

Understand industry trends, capital markets, and transaction opportunities through Tianchao Insights.

联系我们 →